Elevated transgelin/TNS1 expression is a potential biomarker in human colorectal cancer
Metrics: PDF 1494 views | HTML 2382 views | ?
Huimin Zhou1,*, Yiming Zhang2,*, Lihao Wu1, Wenrui Xie1, Lan Li1, Yu Yuan1, Yu Chen1, Ying Lin3 and Xinxiang He1
1Department of Gastroenterology and Hepatology, The First Affiliated Hospital, School of Clinical Medicine of Guangdong Pharmaceutical University, Guangzhou, China
2Department of Urology, Zhujiang Hospital, Southern Medical University, Guangzhou, China
3Department of Gastroenterology and Hepatology, The Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China
*These authors have contributed equally to this work
Huimin Zhou, email: [email protected]
Ying Lin, email: [email protected]
Xinxiang He, email: [email protected]
Keywords: transgelin; TNS1; prognosis; colorectal cancer
Received: September 06, 2017 Accepted: December 04, 2017 Published: December 15, 2017
Transgelin is an actin-binding protein that regulates cell motility and other important cellular functions. Previous studies have suggested that transgelin expression is associated with cancer development and progression, but its specific role in colorectal cancer (CRC) remains controversial. We analyzed expression of transgelin and its candidate downstream target, tensin 1 (TNS1), in CRC patients using the ONCOMINE, Protein Atlas, and OncoLnc databases. Transgelin and TNS1 mRNA and protein levels were higher in CRC patients and CRC cell lines than in normal tissues and cells. Survival analyses using the OncoLnc database revealed that elevated TAGLN/TNS1 levels were associated with a poor overall survival in CRC patients. Transgelin suppression using siRNA decreased TNS1 expression in CRC cells, demonstrating that transgelin induces the TNS1 expression. Importantly, suppression of transgelin or TNS1 using siRNA decreased proliferation and invasiveness of CRC cells. These results suggest that transgelin/TNS1 signaling promotes CRC cell proliferation and invasion, and that transgelin/TNS1 expression levels could potentially serve as a prognostic and therapeutic target in CRC patients.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.